IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Adenovirus Vectors: Excellent Tools for Vaccine Development

  • Jun Chang (Graduate School of Pharmaceutical Sciences, Ewha Womans University)
  • Received : 2020.12.23
  • Accepted : 2021.01.17
  • Published : 2021.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Adenovirus was originally used as a vector for gene therapy. In recent years, with the development of the next-generation vectors with increased safety and high immunogenicity to transgene products, its utility as a vaccine vector has continued to increase. Adenovirus-based vaccines are currently being tested not only to prevent various infectious diseases but also to be applied as cancer vaccines. In this review, I discuss the innate and adaptive aspects of the immunological characteristics of adenovirus vectors and further examine the current status of advanced adenovirus-based vaccine development. Various methods that can overcome the limitations of currently used adenoviruses as vaccine vehicles are also discussed. Through this study, I hope that vaccine development using adenovirus vectors will be expedited and more successful.

Keywords

Acknowledgement

This study was supported by a grant of the National Research Foundation (grant No. NRF-2018R1A2B6002388) and Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (grant No. HV20C0049).

References

  1. Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, Alvira MR, Marsh J, Ertl HC, Wilson JM. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001;75:11603-11613. https://doi.org/10.1128/JVI.75.23.11603-11613.2001
  2. Afkhami S, Yao Y, Xing Z. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol Ther Methods Clin Dev 2016;3:16030.
  3. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther 2009;17:1333-1339. https://doi.org/10.1038/mt.2009.130
  4. Majhen D, Calderon H, Chandra N, Fajardo CA, Rajan A, Alemany R, Custers J. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther 2014;25:301-317. https://doi.org/10.1089/hum.2013.235
  5. Bolinger B, Sims S, Swadling L, O'Hara G, de Lara C, Baban D, Saghal N, Lee LN, Marchi E, Davis M, et al. Adenoviral vector vaccination induces a conserved program of CD8(+) T cell memory differentiation in mouse and man. Cell Reports 2015;13:1578-1588. https://doi.org/10.1016/j.celrep.2015.10.034
  6. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 1994;91:8802-8806. https://doi.org/10.1073/pnas.91.19.8802
  7. Kovesdi I, Hedley SJ. Adenoviral producer cells. Viruses 2010;2:1681-1703. https://doi.org/10.3390/v2081681
  8. Wang Q, Finer MH. Second-generation adenovirus vectors. Nat Med 1996;2:714-716. https://doi.org/10.1038/nm0696-714
  9. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A 1996;93:5731-5736. https://doi.org/10.1073/pnas.93.12.5731
  10. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996;93:13565-13570. https://doi.org/10.1073/pnas.93.24.13565
  11. Tamanini A, Nicolis E, Bonizzato A, Bezzerri V, Melotti P, Assael BM, Cabrini G. Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J Virol 2006;80:11241-11254. https://doi.org/10.1128/JVI.00721-06
  12. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003;10:935-940. https://doi.org/10.1038/sj.gt.3302036
  13. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004;10:616-629. https://doi.org/10.1016/j.ymthe.2004.07.013
  14. Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev 2000;173:89-97. https://doi.org/10.1034/j.1600-065X.2000.917309.x
  15. Napier RJ, Adams EJ, Gold MC, Lewinsohn DM. The role of mucosal associated invariant T cells in antimicrobial immunity. Front Immunol 2015;6:344.
  16. Provine NM, Amini A, Garner LC, Dold C, Hutchings C, FitzPatrick MEB, Reyes LS, Chinnakannan S, Oguti B, Raymond M, et al. Activation of mait cells plays a critical role in viral vector vaccine immunogenicity. bioRxiv 2019. doi: 10.1101/661397.
  17. Yao Y, Jeyanathan M, Haddadi S, Barra NG, Vaseghi-Shanjani M, Damjanovic D, Lai R, Afkhami S, Chen Y, Dvorkin-Gheva A, et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell 2018;175:1634-1650.e17. https://doi.org/10.1016/j.cell.2018.09.042
  18. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, Zhou D, Lin SW, Bian A, Xiang ZQ, Iparraguirre A, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007;110:1916-1923. https://doi.org/10.1182/blood-2007-02-062117
  19. Santra S, Seaman MS, Xu L, Barouch DH, Lord CI, Lifton MA, Gorgone DA, Beaudry KR, Svehla K, Welcher B, et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005;79:6516-6522. https://doi.org/10.1128/JVI.79.10.6516-6522.2005
  20. Li JX, Hou LH, Meng FY, Wu SP, Hu YM, Liang Q, Chu K, Zhang Z, Xu JJ, Tang R, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health 2017;5:e324-e334. https://doi.org/10.1016/S2214-109X(16)30367-9
  21. Yang TC, Millar J, Groves T, Grinshtein N, Parsons R, Takenaka S, Wan Y, Bramson JL. The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol 2006;176:200-210. https://doi.org/10.4049/jimmunol.176.1.200
  22. Lasaro MO, Haut LH, Zhou X, Xiang Z, Zhou D, Li Y, Giles-Davis W, Li H, Engram JC, Dimenna LJ, et al. Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques. Mol Ther 2011;19:417-426. https://doi.org/10.1038/mt.2010.238
  23. Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol 2013;31:137-161. https://doi.org/10.1146/annurev-immunol-032712-095954
  24. Haddadi S, Vaseghi-Shanjani M, Yao Y, Afkhami S, D'Agostino MR, Zganiacz A, Jeyanathan M, Xing Z. Mucosal-pull induction of lung-resident memory CD8 T cells in parenteral tb vaccine-primed hosts requires cognate antigens and CD4 T cells. Front Immunol 2019;10:2075.
  25. Jeyanathan M, Yao Y, Afkhami S, Smaill F, Xing Z. New tuberculosis vaccine strategies: Taking aim at unnatural immunity. Trends Immunol 2018;39:419-433. https://doi.org/10.1016/j.it.2018.01.006
  26. Turner DL, Bickham KL, Thome JJ, Kim CY, D'Ovidio F, Wherry EJ, Farber DL. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol 2014;7:501-510. https://doi.org/10.1038/mi.2013.67
  27. Uddback IE, Pedersen LM, Pedersen SR, Steffensen MA, Holst PJ, Thomsen AR, Christensen JP. Combined local and systemic immunization is essential for durable T-cell mediated heterosubtypic immunity against influenza A virus. Sci Rep 2016;6:20137.
  28. Kim MH, Kang JO, Kim JY, Jung HE, Lee HK, Chang J. Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus. Antiviral Res 2019;163:19-28. https://doi.org/10.1016/j.antiviral.2019.01.002
  29. Uddback I, Cartwright EK, Scholler AS, Wein AN, Hayward SL, Lobby J, Takamura S, Thomsen AR, Kohlmeier JE, Christensen JP. Long-term maintenance of lung resident memory T cells is mediated by persistent antigen. Mucosal Immunol 2021;14:92-99. https://doi.org/10.1038/s41385-020-0309-3
  30. Bolinger B, Sims S, O'Hara G, de Lara C, Tchilian E, Firner S, Engeler D, Ludewig B, Klenerman P. A new model for CD8+ T cell memory inflation based upon a recombinant adenoviral vector. J Immunol 2013;190:4162-4174. https://doi.org/10.4049/jimmunol.1202665
  31. Klenerman P. The (gradual) rise of memory inflation. Immunol Rev 2018;283:99-112. https://doi.org/10.1111/imr.12653
  32. Snyder CM, Cho KS, Bonnett EL, van Dommelen S, Shellam GR, Hill AB. Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 2008;29:650-659. https://doi.org/10.1016/j.immuni.2008.07.017
  33. Lee LN, Bolinger B, Banki Z, de Lara C, Highton AJ, Colston JM, Hutchings C, Klenerman P. Adenoviral vaccine induction of CD8+ T cell memory inflation: impact of co-infection and infection order. PLoS Pathog 2017;13:e1006782.
  34. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 2020;20:615-632. https://doi.org/10.1038/s41577-020-00434-6
  35. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396:479-488. https://doi.org/10.1016/S0140-6736(20)31605-6
  36. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020;395:1845-1854. https://doi.org/10.1016/S0140-6736(20)31208-3
  37. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111. https://doi.org/10.1016/S0140-6736(20)32661-1
  38. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021;396:1979-1993. https://doi.org/10.1016/S0140-6736(20)32466-1
  39. Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 2020;586:583-588. https://doi.org/10.1038/s41586-020-2607-z
  40. Coughlan L, Mullarkey C, Gilbert S. Adenoviral vectors as novel vaccines for influenza. J Pharm Pharmacol 2015;67:382-399. https://doi.org/10.1111/jphp.12350
  41. Sayedahmed EE, Elkashif A, Alhashimi M, Sambhara S, Mittal SK. Adenoviral vector-based vaccine platforms for developing the next generation of influenza vaccines. Vaccines (Basel) 2020;8:574.
  42. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-335. https://doi.org/10.1038/415331a
  43. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-1893. https://doi.org/10.1016/S0140-6736(08)61591-3
  44. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008;372:1894-1905. https://doi.org/10.1016/S0140-6736(08)61592-5
  45. Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 2010;5:386-390. https://doi.org/10.1097/COH.0b013e32833cfe4c
  46. Baden LR, Karita E, Mutua G, Bekker LG, Gray G, Page-Shipp L, Walsh SR, Nyombayire J, Anzala O, Roux S, et al. Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial. Ann Intern Med 2016;164:313-322. https://doi.org/10.7326/M15-0880
  47. Wohlfart C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol 1988;62:2321-2328. https://doi.org/10.1128/jvi.62.7.2321-2328.1988
  48. Hong SS, Habib NA, Franqueville L, Jensen S, Boulanger PA. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J Virol 2003;77:10366-10375. https://doi.org/10.1128/JVI.77.19.10366-10375.2003
  49. Olive M, Eisenlohr L, Flomenberg N, Hsu S, Flomenberg P. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther 2002;13:1167-1178. https://doi.org/10.1089/104303402320138952
  50. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006;441:239-243. https://doi.org/10.1038/nature04721
  51. O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999;10:1349-1358. https://doi.org/10.1089/10430349950018021
  52. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 2003;77:10780-10789. https://doi.org/10.1128/JVI.77.20.10780-10789.2003
  53. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, Feldmann H, Kobinger GP. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008;3:e3548.
  54. Yu JR, Kim S, Lee JB, Chang J. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol 2008;82:2350-2357. https://doi.org/10.1128/JVI.02372-07
  55. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011;85:4222-4233. https://doi.org/10.1128/JVI.02407-10
  56. Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, Wilson JM, Ertl HC. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002;76:2667-2675. https://doi.org/10.1128/JVI.76.6.2667-2675.2002